Domestic pharma major, Dr Reddy’s Laboratories (DRL) has announced its 2QFY04 results. On a standalone basis, DRL has reported an 11% increase in topline and a 5% rise in bottomline. While the bulk drugs and formulations business saw modest growth, the generics and diagnostics businesses acted as dampeners. On a consolidated basis, while the group has reported a 13% rise in net sales, net profit has dropped by 15%. In this context, let us undertake a detailed review of the company’s performance during the period.
Results at a glance (standalone)...
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares
Diluted Earnings per share*
DRL’s topline growth was fuelled by a strong rise in bulk drug sales. The European and domestic markets were the key growth drivers in this business. In the European markets, launch of ‘Ramipril’ contributed Rs 380 m to the revenues. In the domestic market, increase in volumes of key products led the growth. However, bulk drug revenues from the North American market saw a sharp decline due to poor showing by ‘Nizatidine’.
In the formulations business, DRL saw a modest 6% growth. Although DRL showed strong performance in the domestic market due to the company’s strategy of focusing on key brands, the growth was offset by the decline in the revenues from ‘Ciprolet’ and ‘Becelac’ and discontinuance of certain brands due to the rationalisation exercise undertaken by the company. On the basis of therapeutic segments, gastro (20% growth), dental (16%) and cardiovascular (14%) were the top performers. However, naturals (33% drop), specialty (10%) and anti-infectives (3%) saw a drop in revenues. In the international market, formulations sales were affected due to a decline in the revenues from Russia. In Russia, longer custom clearance process resulted in delay in delivery and lower revenues.
However, the growth in the above business was offset by DRL’s dismal performance in the generics business. Revenues from ‘Tizanidine’ from North America dropped from Rs 337 m in 2QFY03 to Rs 212 m in 2QFY04. Revenues from the critical care and biotechnology segment dropped on account of the closure of diagnostics operations in 1QFY04.
Revenue mix by segment
Diagnostics, Critical Care and Biotechnology
On the operations front, although a change in product and market mix helped DRL improve its efficiencies, a rise in legal and R&D expenses resulted in a marginal drop in operating profit margins. R&D expenses increased by 29% to Rs 490 m due to an increase in the number of projects in the areas of Generics and Specialty and higher development activity in APIs. However, higher depreciation and tax provision (due to higher deferred tax) has resulted in DRL recording a meager 5% growth in PAT.
During 2QFY04, DRL has invested Rs 77 m in Aurigene Discovery Technologies and Aurigene Inc, bringing the total investments to Rs 927 m. The company made a further Rs 18 m investment in its subsidiary in Brazil, Rs 90 m in its subsidiary in Netherlands, Rs 29 m in its joint venture in China and Rs 251 for acquisition of land for future R&D initiatives. DRL also incurred normal capital expenditure of Rs 460 m during 2QFY04.
At Rs 1130, DRL is trading at a P/E of 21x its annualised 1HFY04. DRL has increased its R&D thrust and is focusing on Para IV ANDA filings. This coupled with the pending approval of Amlodipine Maleate could translate into higher growth in revenus going forward. However, the approval of Amlodipine Maleate is in under litigation and the company does not have any major drug launch in the near term. This is a cause for concern.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407